From Rs 5.83 to Rs 29.69 Per Share in Just 11 Months & 10 Days: Multibagger Pharma Stock Hit Upper Circuit for Second Straight Day
The stock gave multibagger returns of over 400 per cent from its 52-week low of Rs 5.82 per share.
On Tuesday, shares of Sudarshan Pharma Industries Ltd were locked in a 5 per cent upper circuit to Rs 29.69 per share from its previous closing of Rs 28.28 per share. The stock’s 52-week high is Rs 53.50 per share while its 52-week low is Rs 5.82 per share. The stock has been hitting the upper circuit for the second straight day.
Sudarshan Pharma Industries Limited (SPIL), established in 2008 and headquartered in Mumbai, is a prominent contract manufacturer of generic formulations. SPIL caters to a wide range of institutions and healthcare organisations operating across diverse segments, including speciality chemicals, intermediates, APIs, pharmaceutical and formulation generics, and bulk supply. Beyond its contract manufacturing services, SPIL has ventured into branded products through its Vimac Healthcare division. A significant portion of its product portfolio, consisting of 56 out of 96 items, is registered under the "R" trademark. Furthermore, SPIL collaborates with renowned Indian companies and institutional clients, offering contract manufacturing services for pharmaceutical formulations and medicines.
India's pharmaceutical market is a global powerhouse, projected to grow from USD 42 billion in 2021 to a potential USD 120-130 billion by 2030, making it the largest supplier of generic drugs and a significant contributor to global medicine and vaccine supply. Sudarshan Pharma Industries Limited (SPIL), active since around 2008, exports internationally, focuses on R&D through its subsidiary Ratna Lifescience, and is expanding its capabilities with acquisitions and a new R&D center in Pune expected by March 2025, supported by its new Palghar manufacturing unit.
DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.
According to the half-yearly results, the net sales increased by 19 per cent to Rs 277 crore and net profit increased by 43 per cent to Rs 7 crore in H2FY25 compared to H2FY24. In its annual results, the net sales increased by 9 per cent to Rs 505 crore and net profit increased by 45 per cent to Rs 16 crore in FY25 compared to FY24. The company has a market cap of Rs 715 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The company is aiming to increase their profit margin when it resells Active Pharmaceutical Ingredients (API) within India. This strategy led to a notable increase in their EBITDA margin in the second half of the financial year 2025 (H2FY25), which resulted in a substantial growth in their Profit After Tax (PAT) for the same period.
On November 22, 2024, the shares of the company ex-traded sub-division /stock split of the company’s 1 (one) equity share having a face value of R 10 each fully paid-up, into 10 equity shares of the company having a face value of Re 1 each fully paid-up. In March 2025, FIIs bought 1,29,48,000 shares and increased their stake to 18.45 per cent compared to September 2024. The stock gave multibagger returns of over 400 per cent from its 52-week low of Rs 5.82 per share.
Disclaimer: The article is for informational purposes only and not investment advice.